Raloxifene News and Research

RSS
Raloxifene is an oral selective estrogen receptor modulator (SERM) that has oestrogenic actions on bone and anti-oestrogenic actions on the uterus and breast. It is used in the prevention of osteoporosis in postmenopausal women.
Study indicates estrogenic drug could help treat schizophrenia

Study indicates estrogenic drug could help treat schizophrenia

Low doses of lasofoxifene reduce all common problems in postmenopausal women: Study

Low doses of lasofoxifene reduce all common problems in postmenopausal women: Study

NICE guidelines limit options for low cost osteoporosis drugs

NICE guidelines limit options for low cost osteoporosis drugs

Turmeric and pepper may play a role in preventing breast cancer

Turmeric and pepper may play a role in preventing breast cancer

Patents listed in FDA's Orange Book for Eli Lilly’s Evista invalidated

Patents listed in FDA's Orange Book for Eli Lilly’s Evista invalidated

Court rules in favor of Eli Lilly for Evista's method-of-use patents

Court rules in favor of Eli Lilly for Evista's method-of-use patents

Breast cancer prevention drugs may negatively affect patients

Breast cancer prevention drugs may negatively affect patients

Phase 3 clinical study results of bazedoxifene released

Phase 3 clinical study results of bazedoxifene released

Research data reveals why women discontinue treatment with current osteoporosis therapies

Research data reveals why women discontinue treatment with current osteoporosis therapies

Pregabalin shows potential as treatment for hot flashes

Pregabalin shows potential as treatment for hot flashes

Cancer rates among U.S. elderly, minorities set to explode

Cancer rates among U.S. elderly, minorities set to explode

Study predicts dramatic growth in cancer rates among US elderly, minorities

Study predicts dramatic growth in cancer rates among US elderly, minorities

Lilly granted preliminary injunction to prevent launch of generic Raloxifene

Lilly granted preliminary injunction to prevent launch of generic Raloxifene

Systematic estimation of breast cancer risk appears justified in postmenopausal women

Systematic estimation of breast cancer risk appears justified in postmenopausal women

Eli Lilly granted temporary restraining order to halt launch of generic Raloxifene

Eli Lilly granted temporary restraining order to halt launch of generic Raloxifene

Breast cancer common among women with family history but without BRCA1 or BRCA2 mutation

Breast cancer common among women with family history but without BRCA1 or BRCA2 mutation

Gail model no better than coin flip in predicting risk of breast cancer

Gail model no better than coin flip in predicting risk of breast cancer

Anti-estrogen drug therapy reduces risk of invasive breast cancer in older women

Anti-estrogen drug therapy reduces risk of invasive breast cancer in older women

Reduced incidence of invasive breast cancer with Raloxifene among women at increased coronary risk

Reduced incidence of invasive breast cancer with Raloxifene among women at increased coronary risk

First patient enrolled in phase III study of Bevacizumab and Trastuzumab in early breast cancer

First patient enrolled in phase III study of Bevacizumab and Trastuzumab in early breast cancer